Merck & Co., Inc. (MRK) Earnings Call Transcript & Summary
October 27, 2022
Earnings Call Speaker Segments
Peter Dannenbaum
executiveGood morning, and thanks for joining us on Merck's conference call for the third quarter of 2022. On the line today, we'll hear from Rob Davis, our President and Chief Executive Officer; Caroline Litchfield, our Chief Financial Officer; and Dr. Dean Li, who serves as President of Merck Research Labs. Prior to beginning, there are several points I want to flag. In our GAAP results, you'll notice certain items, including charges tied to acquisitions, costs from restructuring, and some other things as well. Keep in mind that these have been removed from our non-GAAP results, and a reconciliation appears in the press release. Let me also remind everyone that a number of the remarks we're making today could qualify as forward-looking statements under the Safe Harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Those statements reflect Merck management's present beliefs and carry substantial risks and uncertainties. Should our underlying assumptions turn out to be wrong, or should uncertainties come to pass, actual results could end up differing materially from what those forward-looking statements set forth. In our SEC filings, including Item 1A in the 2021 10-K, we identify specific risk factors and cautionary statements that might lead the company's actual results to diverge materially from any projections contained in the forward-looking statements we make this morning. Merck has no obligation to publicly update any forward-looking statements. A slide presentation will run alongside our speakers' prepared remarks during today's call. That presentation, along with today's earnings release and our SEC filings, has been posted to the Investor Relations section of Merck's website. With all that said, I'll hand things over to Rob.
Rob Davis
executiveThank you, Peter. Good morning, and I appreciate everyone being on today's call. The solid results we posted this quarter show continued momentum behind our main growth drivers, along with consistent advancement in our pipeline. We're in a good spot to finish the year strongly, and we're eager to carry that momentum into 2023 and past that; we're making good on our strategic priorities and performing well on the scientific, operational and commercial fronts. Consequently, our pipeline keeps moving forward, the business remains in good shape, our growth pillars hold firm, and our financial results are robust. We stay sharply focused on maintaining that success through ongoing growth and by creating long-term value for patients and shareholders. So, starting with our results; once again this quarter we're happy to report outstanding growth in revenue and underlying earnings. Demand remains strong for our innovative human and animal health portfolios, including products like KEYTRUDA, GARDASIL, BRIDION and BRAVECTO. Our revised guidance captures what we expect will be truly exceptional growth for the full year. Now to our research organization, where we've achieved significant progress across several therapeutic areas. In cardiovascular, top line results from the STELLAR Phase 3 trial, which assessed sotatercept in patients with pulmonary arterial hypertension, met success on the primary endpoint and on nearly all secondary endpoints, pointing to the possibility of transforming how patients with this devastating disease are treated. I take pride in how quickly our research organization acted after last year's acquisition of Acceleron to push sotatercept's development forward. We keep advancing additional programs throughout our extensive cardiovascular pipeline, among them our Factor XI inhibitor, which just got an FDA Fast Track designation for patients with end-stage renal disease. On the oncology side, at ESMO we shared encouraging results from across our wide portfolio and promising pipeline. Long-term survival data strengthens the case for the lasting benefits of KEYTRUDA and Lynparza in certain patients. We're still excited about what KEYTRUDA could do in earlier stages of cancer and when combined with other agents. In vaccines, we introduced VAXNEUVANCE for the pediatric setting and are moving ahead with our Phase 3 trial of V116 in adults, a key piece of our population-specific strategy for invasive pneumococcal disease and part of wider efforts to deliver strong protection to infants as well as adults. And last, in HIV, we're glad there's a path forward for islatravir clinical trials in the treatment setting; we stay dedicated to helping meet unmet needs in treatment and prevention alike. Shifting to sustainability, we keep delivering on our priorities, which further shows our long-standing dedication to creating value for society, and that in turn generates value for shareholders. In August, we released our annual ESG progress report, offering a thorough look at our sustainability strategy, the initiatives we have underway and how we're doing against our goals. True to our mission, we concentrate on access to health, making sure our inventions get to as many patients as possible. In order to make our medicines and vaccines accessible, we are dedicated to finding and producing them in a responsible manner, to surfacing our finest concepts by empowering our skilled and varied workforce, and to conducting ourselves at all times with robust ethics and principles. Among our efforts are a pledge to supply 91.5 million doses of HPV vaccines in countries supported by Gavi, furthering our objective of reaching carbon neutrality by 2025, and backing projects and partnerships in our priority areas via the issuance of an inaugural $1 billion sustainability bond. Our sustainability strategy helps drive and facilitate our business approach in a manner consistent with our operational priorities. This renders us both a stronger enterprise and a global citizen, generating value for society as well as for shareholders. Last night, we also shared that Ken Fraser will step down from his position as Chairman of Merck’s Board of Directors at the conclusion of November. I am certain I express the sentiment of the whole company and our Board in offering our profound gratitude for Ken, his foremost leadership, reverence for science, enthusiasm for connecting with employees across the globe, dedication to patients and health equity, and contributions to communities worldwide. On a personal note, I am exceedingly thankful for the inspiration, mentorship, and backing Ken has given me. Going forward, I anticipate collaborating with the Board in my new capacity as Chairman as we keep building upon Ken’s legacy and advancing what is central to our purpose of employing cutting-edge science to save and enhance lives across the world. I have no doubt that we possess the essential components to attain sustainable growth and value creation. This is demonstrated by our exceptional group of scientists and our colleagues everywhere who are devoted to finding, creating, and providing transformative medicines and vaccines. I hold great confidence in our company’s near- and long-term prospects, and I look forward to sharing further progress as we advance into the future. With that, I will hand the call over to Caroline.
Caroline Litchfield
executiveThank you, Rob. Good morning. For our business, 2022 remains a year delivering outstanding results. Once again this quarter we posted remarkable growth in revenue and underlying earnings, propelled by demand for our innovative portfolio. These outcomes strengthen our dedication to a science-led strategy, made possible through flawless execution by our committed colleagues worldwide; we feel confident about continuing to deliver over the short-term, even as we make disciplined investments aimed at maximizing long-term value for patients and shareholders. Revenues for the total company reached $15 billion, up 14%. If you exclude LAGEVRIO, the business still delivered robust growth of 10%. Underlying growth came in 4 percentage points higher, reflecting the increasing headwind from foreign exchange. Everything else I have to say about revenue will use figures that leave out exchange effects. Momentum continued in Human Health, which expanded 19% — or 15% if you take LAGEVRIO out of the picture — driven by gains across our main pillars. Animal Health turned in a good quarter, posting a 4% sales increase for companion animal and livestock offerings alike. Let's now turn to the third-quarter results for our major brands. On the oncology side, KEYTRUDA climbed 26% to reach $5.4 billion, driven by strong demand worldwide and continued label expansion into additional indications. Stateside, the product grew across all major tumor types and continued to gain from use in earlier-stage disease, including triple-negative breast cancer, as well as select renal cell carcinoma and melanoma cases. Catching cancer at an earlier point in its course can lead to improved outcomes for patients, and that's why our enthusiasm remains high about what KEYTRUDA is doing for people facing these early-stage cancers. It's also worth noting that demand is still very robust in the neoadjuvant, adjuvant, high-risk, early-stage triple-negative breast cancer setting — evidence of just how meaningful KEYTRUDA's benefit is for those battling this aggressive disease. When it comes to metastatic disease, KEYTRUDA continues to hold the top spot in non-small cell lung cancer. Outside the U.S., the growth of KEYTRUDA is still being fueled by adoption in non-small cell lung cancer, head and neck cancer, and renal cell carcinoma. Some earlier-stage indications that were approved not long ago — among them specific high-risk, early-stage triple-negative breast cancer and renal cell carcinoma — have gotten off to a very solid start after launching in major European markets earlier this year. Lynparza kept its place as the leader among PARP inhibitors. Alliance revenue for us rose 23%, powered by ongoing demand in certain patients with high-risk, early-stage breast cancer, as shown by the OlympiA study. We continue to see a promising future for Lynparza. Should it secure approval, our confidence is high that it can benefit individuals suffering from metastatic castration-resistant prostate cancer, supported by findings from the PROPEL study. Revenue from the Lenvima alliance rose 11%, with robust U.S. demand from ongoing adoption in advanced renal cell carcinoma and endometrial cancer partly counterbalanced by the timing of shipments in China. Finally, WELIREG is delivering results in line with what we anticipated, offering a therapeutic choice for the considerable unmet need among patients with certain VHL-associated tumors. Our vaccines segment posted outstanding growth, driven by GARDASIL, which climbed 20% to reach $2.3 billion. Demand fundamentals remain solid in markets beyond the U.S., particularly China, and that is what is propelling our expansion. China's National Medical Products Administration just granted us approval to broaden GARDASIL 9's use to girls and women between 9 and 45 years old, and that widens the opportunity further in this key market. On the U.S. side, the growth came from the timing of CDC purchases, and that's going to hurt sales in the fourth quarter. Given how well GARDASIL has proven to prevent certain HPV-related cancers and other diseases, we're confident we can keep growing it sustainably. Immunization levels worldwide are still low, which hands us a huge chance to help more patients; and we've put aggressive investment into manufacturing capacity, which leaves us well positioned to meet the demand we anticipate both now and over the long term. Within our hospital acute care portfolio, BRIDION sales climbed 22%, lifted by greater market share among neuromuscular blockade reversal agents along with more surgical procedures. As I said before, Animal Health sales rose 4%. Livestock sales were up thanks to poultry products and ruminant technology solutions. Growth in companion animal sales came from the BRAVECTO line of products, partly offset by supply challenges affecting certain vaccines. Moving on, let me walk you through the remaining parts of our profit and loss statement. Everything I say here will be on a non-GAAP basis. We posted a gross margin of 77%, which is a gain of 0.2 percentage points. That improvement came from a beneficial mix of products as well as foreign exchange, though it was partially counterbalanced by pressure from LAGEVRIO and supply sales, which carry thinner margins. Operating expenses reached $6 billion all told, and that figure includes $619 million in payments connected to certain collaborations and licensing agreements. Excluding those payments, operating expenses were up 13%, driven higher by increased investments behind our main growth drivers and pipeline. Other expense was about $100 million, which mirrors a reduction in pension expense compared with the prior year. Our tax rate stood at 13.6%. When everything is accounted for, our earnings came to $1.85 per share. That figure reflects $0.22 in charges related to a major collaboration and licensing agreement. If you set those charges aside, the growth in our underlying business was outstanding. Now I'd like to discuss our 2022 non-GAAP guidance. Because our operations are performing well, we're in a position to lift and tighten our revenue outlook for the entire year. Revenue is now projected to land somewhere between $58.5 billion and $59 billion, and that includes LAGEVRIO sales ranging from $5.2 billion to $5.4 billion. At the upper end, our revised revenue range translates into growth of 20% to 21%. As for foreign exchange, the anticipated impact now incorporates an additional headwind of almost 1% based on mid-October rates, bringing the total negative effect for the full year to roughly 4%. Excluding currency fluctuations and LAGEVRIO, our anticipated expansion is about 16%. For gross margin, we continue to forecast a range of 74% to 74.5%. We are lifting and tightening our estimate for operating expenses to somewhere between $21.3 billion and $21.7 billion, largely driven by a $250 million outlay connected to the recent decision to exercise our option for co-developing a personalized cancer vaccine as part of our existing partnership with Moderna. Bear in mind, our outlook does not factor in any further major business development deals that could potentially occur. We continue to project other expense at approximately $500 million; for the entire year, we anticipate a tax rate near 14%. We are working with an assumption of 2.54 billion shares outstanding. Bringing all those factors together, we have lifted and narrowed the range for expected EPS to between $7.32 and $7.37, representing a $0.05 bump at the midpoint. On its own, the operational momentum within our business would have produced an increase of roughly $0.20 in our guidance. However, that gain is partially being canceled out by the option payments related to Moderna and an added foreign exchange headwind of nearly 1%, based on mid-October rates. Our guidance demonstrates confidence in the fundamental strength of our business. We continue to show strong momentum, and we anticipate lasting underlying demand across our key pillars, such as KEYTRUDA, GARDASIL and Animal Health. As you work through your model, there are several points to bear in mind. We do have an active revenue hedging program for foreign exchange, and even so, FX is still dragging on growth. That's especially true for products that bring in more of their sales from outside the U.S., like what we see in Animal Health. The hedging program does cushion the FX effect. And if foreign exchange keeps acting as a headwind that shows up at the product level, then other revenues will pick up a benefit. On top of that, supply sales to Organon are part of other revenue. As our results showed, PNEUMOVAX23 is under pressure, especially here in the U.S. Given the ongoing change in the marketplace toward more recent adult pneumococcal conjugate vaccines, our dedication to capital allocation priorities stays firm. Investments aimed at our pipeline and operations will keep coming first, since they fuel growth both now and over time throughout our portfolio. Dean will discuss how much ground we've gained in our pipeline, progress that could support lasting revenue increases. To strengthen that pipeline, we're directing the strongest science from outside into business development that adds value, and we'll put money behind it to capture what these products can deliver. Every corner of the business development landscape remains under review for us. Our balance sheet gives us plenty of room, and we'll move only at the point where science and value come together. If significant business development opportunities don't come through, and based on what's in the pipeline for potential deals, we'll take advantage of chances to repurchase shares. Our commitment to the dividend stands, and our aim is to raise it as time goes on. To wrap up, heading into the end of the year, our confidence in the ongoing expansion of our business is unchanged. Demand worldwide for the medicines and vaccines we innovate stays robust, and we keep showing the operational momentum and commercial execution that let us bring value to patients and shareholders today and far ahead. With that, I'll hand the call over to Dean now.
Dean Li
executiveThanks, Caroline. It's good to be able to tell you where things stand now that the second quarter call has passed. The pipeline continues to gain momentum, and it reaches across therapeutic areas, modalities, and development stages — from work we do ourselves to long-standing alliances and business development chances that have come up lately. In cardiology, we're making steady headway on pulmonary arterial hypertension as well as on our PCSK9 and Factor XI programs. When it comes to vaccines, we're moving forward with both discipline and pace, following the VAXNEUVANCE approval and assembling a set of pneumococcal vaccines designed for specific needs. Our oncology portfolio, meanwhile, continues to grow through alliances with Orion, <<inaudible>> and, most recently, Moderna. Every one of these gains strengthens my belief in what's coming through our development queue, and it really underscores the potential that a number of these candidates hold, with each one ready to make a real difference for people living with disease. Like Rob said, we believe there's substantial room to change outcomes in cardiovascular disease. Just a few weeks back, we shared top line data from the Phase 3 STELLAR study, a trial that tested sotatercept for treating pulmonary arterial hypertension. On top of the standard of care medicines that are already approved today, sotatercept delivered a striking result on the main efficacy endpoint — a gain in 6-minute walk distance measured from baseline out to 24 weeks. Notably, 8 out of 9 secondary efficacy outcome measures reached statistical significance, among them the outcome measure of proportion of participants achieving multicomponent improvement and the outcome measure of time to death for the first occurrence of a clinical worsening event. We look forward to sharing these results with regulatory authorities and intend to present the findings at a scientific congress in 2023. Data from the STELLAR trial marks an important milestone as we work to establish a beachhead in pulmonary arterial hypertension. Turning to what's next, sotatercept is being studied in the ZENITH trial for morbidity and mortality, which will make it possible to gauge whether the disease's progression can be reversed. After that comes the HYPERION trial, which is meant to determine if giving sotatercept sooner during the course of PH leads to better outcomes and pushes back the point of clinical worsening. There's also CADENCE, a Phase 2 trial, which looks into what sotatercept might do in left heart failure. In addition to sotatercept, we have MK-5475 under study — an inhaled soluble guanylate cyclase stimulator that is investigational and was created to produce selective pulmonary arterial vasodilation while keeping systemic exposure limited, for treating PAH. Our confidence remains strong that this investigational portfolio holds promise for fundamentally transforming how pulmonary arterial hypertension is treated. Now let's discuss LAGEVRIO. About 2.5 million individuals have gotten this medication to treat COVID-19 as of now, and research keeps demonstrating the difference this oral option makes for patients and for the healthcare system. Evidence from actual practice involving older, high-risk groups in Israel and Hong Kong showed fewer hospitalizations and deaths, which aligns with what the Phase 3 move-out clinical trial found. Not surprisingly, a sizable UK study that looked at a wider, heavily vaccinated population during the omicron period detected no gap in hospitalization compared with standard of care. Still, certain important results came out of particular secondary analyses — specifically, quicker recovery, faster symptom alleviation, and fewer doctor visits. With LAGEVRIO, the safety profile we keep seeing matches what showed up in move-out. The pandemic keeps changing shape, and how many people get vaccinated still differs a great deal between one country and another. More recent variants, omicron among them, tend to cause illness that is less severe; even so, older individuals and those with other health conditions still face a significant chance of a bad outcome. Given that, evidence coming out of real-world studies matters a lot, since we are trying to grasp the ways LAGEVRIO gets used and what good it may do across different groups of patients. As a treatment for COVID-19, LAGEVRIO remains a valuable part of the toolkit, particularly given how uncertain things are around new variants appearing and surges that keep happening worldwide. Beyond COVID-19, we are now working to capture the wide antiviral possibilities of LAGEVRIO; a Phase 2 trial has begun that looks at using it against Respiratory Syncytial Virus, and we will share more news once it is ready. Moving over to our HIV portfolio: after the setback to the islatravir program last year, reviewing the data has taught us a tremendous amount. After talking things over with the FDA, we are glad to say a path forward exists. We've kicked off a brand-new Phase 3 trial. It's evaluating a once-a-day oral combo of doravirine plus a lower dose of islatravir in patients with HIV-1 infection. In addition, the Phase 2 trial we're running with Gilead — the one examining a weekly oral regimen of islatravir and lenacapavir in adults living with HIV-1 who have achieved viral suppression — is resuming, and it will use a reduced amount of islatravir. We continue to believe there's substantial potential in the nucleoside reverse transcriptase translocation inhibitor approach, and we remain committed to addressing unmet needs in both HIV treatment and prevention; in the PeEP space, our focus is on creating our own novel NRTTI compounds. Now let's turn to vaccines, specifically GARDASIL-9. Caroline noted earlier that China's National Medical Products Administration expanded the approved age range for GARDASIL-9 just last month. This clearance highlights the strong clinical data behind GARDASIL-9 and its effectiveness in preventing particular HPV-related cancers and diseases. We also welcomed the European Commission's recent sign-off on VAXNEUVANCE, our 15-valent pneumococcal conjugate vaccine, for use in the pediatric setting. With that decision, a meaningful option becomes available for vulnerable populations, including babies younger than 1 year, a group that typically experiences the greatest disease burden. I'd also like to bring up the Orna Therapeutics collaboration we announced not long ago; we've made considerable investments and gained useful insights into RNA technology. The impressive circular RNA platform Orna built lets us investigate what a new generation of vaccines and therapeutics might achieve. Now turning to oncology. Across tumor type and stages of disease, our oncology portfolio keeps up strong momentum. During the European Society for Medical Oncology Meeting a month ago, we shared data on long-term survival advantages for KEYTRUDA in non-small cell lung cancer, melanoma, and head and neck cancer, plus for Lynparza in ovarian cancer. We also unveiled findings that keep bolstering the case for KEYTRUDA's potential in earlier-stage disease. We're pushing hard on research into earlier-stage disease because that's where the chance of curing cancer may be highest. Also, at ESMO, we shared initial data with Seagen and Astellas from the Phase 1b/2 EV-103 study, specifically the KEYNOTE-869 cohort K. When KEYTRUDA was paired with enfortumab vedotin-ejfv as a first-line option, it led to a promising objective response rate among patients whose urothelial cancer is unresectable, locally advanced, or metastatic and who aren't eligible for cisplatin-based chemotherapy. There's still a major unmet need for new therapies aimed at locally advanced or metastatic bladder cancer, and we're eager to see what this combo could deliver. This quarter, Lynparza paired with abiraterone received priority review as an initial treatment choice for people who have metastatic castration resistant prostate cancer, no matter what their genetic mutation status is, based on findings from the PROpel study. That PDUFA date falls in Q4. Outside America, our oncology approach continues to move forward. In Japan and China, we still have a lot of opportunity to improve results for patients and address needs that aren't yet met. We got four fresh green lights in Japan. The first covers KEYTRUDA combined with chemotherapy for neoadjuvant, adjuvant, high-risk, early-stage triple-negative breast cancer, drawing on KEYNOTE-522. The second is KEYNOTE-564, for adjuvant use in certain renal cell carcinoma patients following surgery. Third comes KEYNOTE-716, again for adjuvant use, in certain individuals aged 12 and up whose Stage 2b or Stage 2c melanoma has been fully resected. And fourth, KEYNOTE-826, covering KEYTRUDA with chemotherapy, with or without bevacizumab, for certain advanced or recurrent cervical cancer patients. Turning to Lynparza, we picked up clearances in the EU and Japan for adjuvant therapy in patients with certain high-risk, early-stage breast cancer types, backed by the OlympiA A trial, plus one in China as first-line maintenance for advanced ovarian cancer patients. Finally, we chose to use our option for joint development of an individualized cancer vaccine known as mRNA-4157, or V940. Our collaborator Moderna is currently testing it together with KEYTRUDA in a Phase 2 study involving individuals who have locally advanced melanoma that has been surgically removed. That Phase 2 trial's primary objective is to determine how a tailored cancer vaccine combined with KEYTRUDA performs relative to KEYTRUDA alone, through a randomized study focused on early-stage melanoma in the adjuvant setting. We are excited to continue our collaboration with Moderna, a pioneer in mRNA vaccine science. To wrap up, we have achieved significant progress across our pipeline, and I look forward to providing additional updates on our advancements in the future. And at this point I'll hand the call back over to Peter.
Peter Dannenbaum
executiveThank you, Dean. Leo, will you please start the Q&A? <<operator_script>>
Chris Schott
analystHello, sounds good. Many thanks. So my question concerned how you're putting capital to work. I believe during the prepared remarks you said that should BD fail to come together, depending on how the pipeline advances, you would look at repo at some later stage; so on that subject, what's your current view of the broader business development environment? And has your leaning toward — or I suppose how actionable larger transactions are compared with Acceleron-style tuck-ins shifted in any way over the course of this year. I realize this is clearly a major topic of discussion around the Merck situation; so I would just like to hear your most recent perspective on the BD environment; and are we moving nearer to a stage where perhaps repo would make sense given the cash that appears to be building up within the company? Thanks.
Rob Davis
executiveRight. Thanks, Chris, for that question, and I'll have Caroline address the share repurchase part specifically. As for the BD environment, honestly, we keep seeing a set of opportunities that interest us and that we keep evaluating; so as things stand right now, our focus and our urgency when it comes to business development have not shifted. We do see a range of possible areas in which to play. Of course, we need to bring those to fruition, which is what we're trying to accomplish. That remains our priority, since we still believe the greatest thing we can do to create long-term value is to put money into the sustainability of our business, meaning putting money into the pipeline of the future, both in what we do internally and via BD; so that is our priority. And I do see opportunities. Yet clearly, we stay committed as well to not sitting on cash. So with that, perhaps I'll turn it over to Caroline to speak specifically about the share repurchase.
Caroline Litchfield
executiveChris, when it comes to where we put our capital, nothing has shifted. We aim to deliver a solid return for shareholders in two ways: the dividend we issue, which we anticipate will rise, and by buying back stock. At the same time, we weigh the requirement to put money into the company to fuel expansion, along with the business development approaches Robert just described. Where things stand now, with our attention on business development and our wish to avoid piling up surplus cash on the balance sheet, we'll consider repurchases of shares when the opportunity looks right, judging by what's in that BD pipeline.
Rob Davis
executiveGreat. Thank you, Chris. Next question please, Leo.
Daina Graybosch
analystYes. I'm curious whether you might expand a bit further on the approach behind your novel pneumococcal vaccines, V116 and V117, and how you expect they'll eventually stack up against rival vaccines whose serotype 3 coverage keeps growing.
Dean Li
executiveThis is Dean. I'll handle that one, and many thanks for asking. The headline point is simply this: our stance is that having additional serotypes doesn't automatically mean a better product, and a single approach won't work for everyone. That's my belief, and it's also what I saw while practicing medicine — you want the correct medicine, or here, the correct vaccine, matched to the correct patient at the correct moment. So consider VAXNEUVANCE, our 15 valent, which delivers repeated responses against serotype 3, plus 22F and 33F. When you examine that alongside the epidemiology of pneumococcal disease, you find a bimodal curve, with the first 2 years of life really mattering, particularly year one. Then on the adult side, you see rates climbing at 45, 55, and 65. Hence a bimodal curve. And if you map out the various serotypes, they differ considerably across those two groups; that's precisely why we see it as the correct vaccine for the correct patient at the correct moment. We also now have a pediatric V114 that has ACIP that's gone through. Regarding differentiation and how it relates to pediatrics, we lack a clear picture of other vaccines, yet we hold strong confidence in our capacity to deliver coverage during year one. And the data so far could indicate that this represents a meaningful point of differentiation in a pediatric study. Certain questions exist around top line serotypes that have been sort of laid out. There's been some talk of 6 serotype 2 substantial, and we can't really speak to that differentiation until we know precisely which serotypes and what the actual detailed data show. As for the adult market, this gives us tremendous insight and tremendous enthusiasm for V116, our 21-valent vaccine; that particular one is aimed specifically at the serotypes that matter for adults. So it's 21-valent, yet I'd stress that 11 serotypes within the 21 valent for V116 aren't covered by PCV20. The reason is our focus sits on adult disease, and we're going after 85% of residual invasive pneumococcal disease; and if I consider the vaccines now in Phase 3, plus those in Phase 2 or Phase 1 with recent data, I'm not aware of anyone else whose vaccine goes after 85% of residual invasive pneumococcal disease; so more isn't better, one size doesn't fit all, the correct vaccine, the correct patient at the correct moment.
Rob Davis
executiveThank you, Daina. Next question please, Leo.
Colin Bristow
analystMorning, and congratulations on these results. GARDASIL had an excellent quarter, though you mention what seems like a one-time effect tied to CDC purchase timing. Could you put a number on how big that effect was? Then I'd also like to check in on the extra supply that's set to arrive in '23, '24, and '25. Does that remain on schedule? And can you say specifically which regions that supply will be coming from? Thanks.
Caroline Litchfield
executiveCaroline here. Let me try to address what you asked. GARDASIL keeps serving as a really powerful engine of growth for us, and that will remain true far into the future, since just 9% of people worldwide who qualify have gotten vaccinated so far. Regarding this quarter's numbers, growth in the U.S. came mostly from the CDC's timing; during 2021's third quarter, the CDC made a buy-in of roughly $125 million. In '22's third quarter, a buy-in of about $250 million occurred. That means, compared with a year earlier, it added to growth by roughly $120 million plus. We anticipate that most of the CDC's buy-in from the third quarter will reverse out across the fourth quarter. When we consider our chance to meet worldwide demand and safeguard as many lives as possible down the road, we'll have backing from added supply and capacity that begins arriving in 2023. That extra supply, we expect, will phase in across '23, '24 and '25. So we stay highly confident about safeguarding more lives and generating growth far into the future, which includes doubling GARDASIL's revenue in 2030 relative to where it stood in 2021.
Peter Dannenbaum
executiveGreat. Thank you, Colin. Next question please Leo.
Seamus Fernandez
analystI appreciate the question very much. What I was hoping to do was ask about sotatercept, and maybe the endpoints that caught you off guard the most. What we hear from thought leaders is that the clinical worsening benefit showing up as soon as it did was a real surprise and points to upside. So I'm curious, Dean, how you see that part of the discussion, and maybe what excites you about some of the earlier-stage clinical studies for sotatercept? Thanks.
Dean Li
executiveMany thanks for asking that; so, yes, top line results were given by us. We're proceeding quickly to bring those data before regulatory authorities across the board. Still, to take a step back, I want to remind at least myself and everyone — and other people that what attracted us to the sotatercept mechanism was its distinct mode of action. It rebalances activin and BMP signaling. Most other mechanisms of action could mostly be seen as vasodilatory, and we have a very robust program aimed at creating the best <<inaudible>> medicine. Yet with the mechanism of action for sotatercept, the expectation would be that it might reprogram how cells respond and essentially modify the disease. The results have us excited; a profound effect on six-minute walk is something we know occurred; yet as you stressed, time to clinical worsening, and these multi-components, all matter greatly, and they arrived clinically meaningful and statistically significant. So our hope is that we can potentially reshape how PAH is treated. I'd stress that we discuss HYPERION, venous and CADENCE. But VICTORIA, the follow-on program, is what I mean. And why that matters so much to me, given the results I observe, is that I very much want the individuals who were on the STELLAR trial to have the chance to enter VICTORIA, an open-label trial, since the effects that we see, which will be reported at a meeting likely in 2023, are ones where we must ensure that those individuals recruited to STELLAR have continued access to sotatercept. That's how important we think the results are.
Peter Dannenbaum
executiveThank you, Seamus. Next question please Leo.
Steve Scala
analystThanks. Rob, you've held the CEO position for 16 months, and soon you'll take on the Chairman role. What do you consider your biggest wins over that stretch? And what's been most disappointing? Considering what you said when you stepped into the job, I think many of us figured more would have gotten done faster on building up the pipeline, particularly because among global pharma companies, Merck's pipeline ranks second smallest. Would you agree that's a fair statement? And if you do, what's the reason things haven't moved along faster? Thanks.
Rob Davis
executiveYeah. Steve, I appreciate that question. Clearly, it's flown by — 16 months in this seat. But what makes me proudest, there are a few things. First, how the whole organization has united as a single team and truly sharpened the focus across the business. Clearly, spinning off Organon, I believe that went very well, and it's left us with simpler structures and greater focus, which I feel really good about. On the business development front, clearly the speed at which we acted with Acceleron, and then you've heard about the truly outstanding data emerging from the STELLAR study, that's something I feel very proud of. Beyond that, I'd point to how our team keeps executing essentially without a hitch — scientifically, operationally, commercially — I couldn't be more proud of everyone's efforts. We've united and we're genuinely delivering on all those fronts, and that's what I'd say I'm very proud about; as for the pipeline itself, I genuinely believe we're achieving a great deal. A year ago, we wouldn't even have been given credit for a cardiovascular pipeline. And now, we're discussing how, in the '24 to '28 timeframe, we might see as many as eight new approvals generating revenue that could exceed $10 billion by the mid-2030s across the full set of assets, some developed in-house and clearly some added through business development, such as what we did with Acceleron. So, I feel really good about that. The strides we're making in vaccines, what we're observing. I believe VAXNEUVANCE doesn't get the recognition it deserves. There's the idea Dean set out of taking a truly bespoke approach, letting us cover more of the serotypes responsible for disease, whether in infants, and then in a selective and different way, those in adults. We see that as a genuine game changer. Our expanding pipeline in neuroscience and immunology — I could keep going — plus the momentum we maintain in strengthening our oncology pipeline. So, do I believe we have everything we need? No. But do I believe we've made tremendous progress in a year? I genuinely do, and that gives me confidence we'll keep driving progress forward. The reality that we completed 3 significant business development agreements just in this quarter, covering mRNA technologies, extending into circular RNA technologies, personalized cancer vaccines, and also more traditional oncology agents featuring a truly novel mechanism — all of those things contribute to the future promise this company holds. So honestly, I feel quite good about it. There's more work ahead, but I have confidence in what we've accomplished up to now.
Peter Dannenbaum
executiveAppreciate it, Steve. Let's take the next one, Leo.
Mara Goldstein
analystWonderful. Pardon me. I really appreciate you taking my question. Since the cardiovascular segment just came up, I'd like to inquire about it; with sotatercept applications currently pending, where do you believe that team still needs to develop from a commercial standpoint, or do you already have the right size in place to get sotatercept launched and reach its full near-term potential?
Rob Davis
executiveSure. Perhaps I'll kick that off, and Caroline or Dean might want to chime in. When you look back through the years, Merck genuinely has built a solid track record and heritage in cardiovascular. And much of that institutional knowledge, so to speak, remains within our company. That leaves me quite confident we possess the necessary resources. Even more significant, though, is that we're already operating in PAH today; Adempas is ours; Verquvo is ours too. As a result, we have representatives engaging with those physicians. Think back to what prompted our interest in Acceleron — it was partly our pipeline findings, but equally what we observed on the commercial side from that firsthand exposure. So the abilities are definitely there. Beyond that, another point worth making is that this situation differs somewhat from how we previously viewed things. In numerous instances, many of these treatments remain specialty products. They aren't really the classic primary care medicines we've grown accustomed to seeing before. My view is that our positioning is quite strong. Consequently, I hold zero concerns regarding our self-assurance and capacity to bring this to market successfully; we've accomplished it before, and we'll accomplish it once more.
Peter Dannenbaum
executiveGreat. Thank you, Mara. Next question please.
Umer Raffat
analystHey everyone, and thanks for letting me ask something. I'd like to dig into a couple of oncology studies specifically. One is the subcu KEYTRUDA study that's running now against IV. I guess I'm just trying to get a sense of how confident you feel about it, and whether it's fair to think that most of the franchise would end up moving over to subcu. Then there's the KEYTRUDA plus KRASG12C study — I'm wondering whether what you've seen so far suggests that kind of combo can actually work. Thanks.
Dean Li
executiveLet me try to address both. First, I'd stress that across the whole field, and at Merck in particular, there's a steady shift toward treating cancer earlier; we've discussed the approvals we hold in early stage for Lynparza as well as KEYTRUDA. The recent Merck-Moderna collaboration is meant to build on that. Basically it's an IO-IO pairing, starting with melanoma, though it could be broadened, taken deeper, and stretched into additional tumor types at various stages. With that in mind, what matters most for patients — particularly early stage — is genuinely strong access to our medicines, plus a need for scientific innovation. That's the reason we're pushing the subcu program forward. We feel confident it will matter and succeed, and it will be truly essential as we shift into early phase, since that ability can't be tied to an infusion center. So our strategy of going into early phase is one we believe in, and it's connected: every bit of scientific innovation is needed to boost access. On the RAS program, I've noted before that among everyone pushing these forward, RAS will need a combination approach. Being able to advance those programs so that you have a dose and can combine with other medicines matters; we have early data from our RAF inhibitor along with many of the features we believe are necessary for that. We're optimistic that the cards may end up reflecting well on our KRAS program, and we'll share that data — monotherapy as well as in combination with pembrolizumab — at the right moment when we present it at a Congress.
Rob Davis
executiveAnd Umer, as for your particular inquiry regarding the conversion, it's likely premature to dive into those particulars. However, what I'd say is that, broadly speaking, we view this as delivering substantial therapeutic advantage. When you consider life quality, particularly as patients progress into the earlier phases of cancer, having the ability to administer the medication via subcutaneous route, in our view, is both novel and will provide genuine worth to those we treat; thus, that forms a component of our approach when we examine the full picture of how we keep serving patients while broadening our franchise. So, that's an area under consideration, though additional specifics will come as we advance further along.
Umer Raffat
analystGreat.
Peter Dannenbaum
executiveThanks Umer. Next question please.
Mohit Bansal
analystThanks a lot, and appreciate you fielding this. Remaining on the topic of sotatercept, particularly regarding the CADENCE study — we had a conversation with a physician, and he was quite enthusiastic about this trial, since no approved treatments exist for that patient subset you're targeting. Could you assist us in setting expectations for this trial, since many of its endpoints closely resemble those of STELLAR? So would you anticipate a comparable degree of efficacy, or might the bar be set lower because no standard of care exists in that setting? Thank you.
Dean Li
executiveYes. Let me address that — we examine both our sotatercept and, I should also highlight, our inhaled soluble guanylate cyclase in much the same overarching way, which is that we're prepared to advance it into PAH; however, when examining the mechanism of action, you ask yourself whether there are additional areas where you could impact diseases that aren't pulmonary arterial hypertension, but rather conditions involving pulmonary hypertension, like diastolic heart failure or, say, lung disease. What we anticipate is wanting to investigate whether sotatercept and its distinctive way of rebalancing specific molecular pathways might likewise be extended to those patients suffering from diastolic heart failure alongside pulmonary hypertension. And considering the effect sotatercept has demonstrated that we've already observed in PAH, that provides us somewhat greater confidence that this mechanism could be relevant for those individuals with diastolic heart failure. The same holds as we progressed our in-house soluble guanylate cyclase.
Dean Li
executiveWhen it comes to PAH, we're additionally looking into whether this molecule might be applicable for patients who have lung disease along with pulmonary hypertension as well; therefore, what we've seen makes us feel more assured about what comes next.
Peter Dannenbaum
executiveGreat. Thank you, Mohit. Next question please Leo.
Chris Shibutani
analystThanks. Building on what Steve asked Rob regarding the thing you take the most pride in — you mentioned how well the Organon spinoff worked out and how it gave an organization a somewhat simpler structure and focus. I'd like to set that beside the question of the animal health business. Share a bit about how you're thinking these days regarding where it sits among capital allocation priorities, and whether you could see it becoming a strategic move you'd weigh, perhaps separating that business. Thanks.
Rob Davis
executiveAbsolutely. Chris, I appreciate the question. Like we've said before, the portfolio is something we constantly review. We're forever asking which structure is best for developing and creating long-term value for our business and for our shareholders; with that lens, our belief remains that animal health is a major growth engine for us. Honestly, it delivers plenty of synergies, and they flow both ways. Clearly, they gain from being able to tap the science on the human health side. We gain from the value they provide and, in certain instances, honestly, on the vaccine side, a few of the manufacturing technologies are in fact being carried across to the human health side. So, synergies do exist between these two businesses, in our view. Our conviction remains that we have the ability to invest fully to maximize the opportunity in animal health. I think we've shown that through the capital we've put to work, and that capital is delivering returns. And I don't think that business would have gotten the capital it's had to grow were it not inside Merck. So, it gains from what we're able to give them. We gain from what it gives us and, as things stand, we still view it as a strategic asset; so, there are no plans to explore spinning it.
Peter Dannenbaum
executiveThanks, Chris. Let's take the next question.
Luisa Hector
analystHi there. I appreciate you taking my question. Perhaps you could go into a bit more detail regarding islatravir, since you feel confident enough to keep its development going. Could you share anything further regarding what effect this drug has on lymphocytes when given at the lower dose? It's clear you're in a position to proceed, and the regulator seems satisfied. Is there a particular degree of lymphocyte reduction that regulators would be willing to permit? Also, what should we make of the possibility that resistance could emerge at the lower dose? And at what point could Phase 3 data become available? Thank you.
Dean Li
executiveI really appreciate that question. Let me stress that within our portfolio of NRTTI molecules, islatravir is a single molecule; and as you noted, we have a strong interest in how significant this collection of molecules and this mechanism are, for both the prep context and the treatment context. It also holds the potential to genuinely reshape the longer-acting arena. To address your specific point, we possess a broad array of clinical data, as many…
Peter Dannenbaum
executiveExcuse me, Dean. Leo, our conference will continue past 9:00 a.m.
Peter Dannenbaum
executiveThank you; we are prepared to go a few extra minutes.
Dean Li
executiveWe've got a wealth of clinical data, then. Our confidence is high that 0.25 milligrams is going to work; we're also confident that lymphocyte and CD4 T-cell effects will be similar to those of any standard antiviral. So that falls under the Q day. Beyond that, we're quite eager to advance to the Q week together with our partner, Gilead. With any luck, more of that will start getting posted, but our attention is on revising the protocol and the dosing regimen while the FDA guides us; I'd also like to stress that our commitment to the two-month oral will remain. Just consider it — 12 pills a year, 12 pills a year for high-risk patients taking with PREP. We've got MK-8527, a distinct molecule within our NRTTI portfolio.
Peter Dannenbaum
executiveAlright. So, to everyone who has stayed connected, I really appreciate it. Due to the technical problems, we need to end the call at this point. If you were waiting in the queue, please reach out to IR, and we’ll aim to address your questions. Thanks so much, everyone.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Merck & Co., Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Merck & Co., Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck & Co., Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.